retatrutide clinical trials phase Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal 3 obesity trial Retatrutide Clinical Trials: 28.7% Weight

Caused by blocked airways, apnea often causes problems in people with obesity because it is thought to increase the volume of tissue pressing down on their windpipe during sleep

Faghris comprehensive research portfolio encompasses the study of occupational health and safety, examining workplace stressors and their impact on chronic diseases such as mental health issues, cardiovascular conditions, obesity, and type 2 diabetes

Retatrutide remains investigational, with Phase 3 trials ongoing and potential approval not expected until mid-2026 or 2027 at the earliest

While medications like Ozempic may help some people jumpstart weight loss, theyre not the onlyor the bestpath for everyone

They are most applicable to facial and neck sagging, including Ozempic face